Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach to Stay at FDA

This article was originally published in RPM Report

Executive Summary

FDA Commissioner Andrew von Eschenbach is poised to remain head of the agency, either in an acting role or as the White House nominee, through the end of the second Bush term. Other candidates were interviewed-including drug safety expert Ray Woosley, MD, but the administration appears to be happy with the job the National Cancer Institute Director is doing.

You may also be interested in...



Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

As DC Speculates on Democrats in 2009, Some Old FDA Hands Come Into View

No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.

Forced to Act: Omnitrope and the Battle for an FDA Commissioner

Generic biologics was not a priority for Andrew von Eschenbach when he accepted the job as acting commissioner of FDA. But two events -- a federal court ruling requiring a decision on Sandoz' Omnitrope NDA and the European Union approval of the follow-on biologic -- mean FDA may be pressed to take action on a regulatory pathway. The Omnitrope ruling makes it more important than ever that FDA have a fully confirmed leader in place, but it will also make it harder to get one.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel